Edwards Lifesciences Action: Kursrückgang for Quartalsbericht ()

The Edwards Lifesciences promotion resulted in a lighter back gait in the last few weeks. With an active exchange rate of EUR 59.61 (as of September 28, 2024), the paper of US-American medical technology has lost 5.84% an year. Trotz dieser kurzfristigen Schwäche lies de Aktie no meer dan 10.56% op de 52-Wochen-Tief. We have aimed to use the new impetus for active cooperation on October 23.

Bewertung und Ausblick

With a Kurs-Gewinn-Verhaaltnis (KGV) of 25.22 for the year 2024, the Bewertung van Edwards Lifesciences Aktie in the Rahmen sector has been published. Experts have developed brand names that occupy a strong position in the Herz-Kreislauf-Medizintechnik and increase the turnover of Investors. The commenden Wochen dared to separate for the fresh Kursentwicklung signal.

Anzeige

Edwards Lifesciences promotion: Buy or sell?! New Edwards Lifesciences Analysis dated September 29, 2018:

The noses of Edwards Lifesciences-Zahlen speak a clear message: Urgent Handlongsbedarf for Edwards Lifesciences-Aktionäre. Do you want to make a purchase or another purchase? The time had come in the free analysis of September 29.

Edwards Lifesciences: Buy or sell? Read more here…